摘要
目的:探析干酪乳杆菌联合康复新液治疗溃疡性结肠炎的效果。方法:将124例溃疡性结肠炎患者纳入研究,按照随机数字表法将患者分为A组(41例)、B组(41例)和C组(42例)。所有患者入院后均接受常规治疗,A组在常规治疗基础上接受康复新液治疗,B组在常规治疗基础上接受干酪乳杆菌治疗,C组在常规治疗基础上接受干酪乳杆菌联合康复新液治疗,3组均连续治疗2个月,并于治疗结束后随访12个月。于治疗2个月,比较3组治疗效果、症状恢复时间,分别于治疗前、治疗4周后检测并比较患者的炎症因子[肿瘤坏死因子-α(TNF-α)、C反应蛋白(CRP)]、免疫因子(CD3^(+)、CD4^(+))、肠道黏膜功能[D-乳酸(D-LD)、二胺氧化酶(DAO)];比较药物不良反应及随访期间复发率。结果:治疗2个月后A、B组临床疗效比较差异无统计学意义(P>0.05),C组治疗总有效率高于A、B组(P<0.05);C组腹泻恢复正常时间、腹痛缓解时间、便血消失时间均短于A、B组(P<0.05),但A、B组组间比较差异无统计学意义(P>0.05);治疗4周,3组TNF-α、CRP水平均较治疗前降低(P<0.05),A、B组TNF-α、CRP水平比较差异无统计学意义(P>0.05),但C组TNF-α、CRP水平低于A、B组(P<0.05);治疗4周,3组CD3^(+)、CD4^(+)水平均较治疗前升高,A、B组CD3^(+)、CD4^(+)水平比较差异无统计学意义(P>0.05),但C组CD3^(+)、CD4^(+)水平高于A、B组(P<0.05);治疗4周,3组D-LD、DAO水平均较治疗前降低(P<0.05),A、B组D-LD、DAO水平比较差异无统计学意义(P>0.05),C组D-LD、DAO水平低于A、B组(P<0.05);3组药物总不良反应发生率比较差异无统计学意义(P>0.05);随访12个月,A组复发率为25.00%(8/32),B组复发率为29.03%(9/31),A、B组间复发率比较差异无统计学意义(P>0.05),C组无复发,复发率低于A、B组(P<0.05)。结论:溃疡性结肠炎患者采用干酪乳杆菌、康复新液治疗均可获益,但相较单一治疗,联合治疗对炎症、免疫功能、肠道黏膜功能的治疗效果更显著且不增加用药安全性风险,复发率低。
Objective:To explore the effect of Lactobacillus casei combined with Kangfuxin solution in the treatment of ulcera-tive colitis.Methods:A total of 124 patients with ulcerative colitis were enrolled into the study and divided into Group A(41 ca-ses),Group B(41 cases),and Group C(42 cases)using a random number table method.All patients received routine treatment upon admission.Besides,Group A received Kangfuxin liquid treatment,Group B received Lactobacillus casei treatment,and Group C received Lactobacillus casei combined with Kangfuxin liquid treatment.All three groups received the treatment for two continuous months and were followed up for six months after treatment.After 2 months of treatment,the therapeutic effects and recovery time of the three groups were compared.The inflammatory factors such as tumor necrosis factor-α(TNF-α)and C-reactive protein(CRP),immune factors including CD3+and CD4+,intestinal mucosal function indexes such as D-lactic acid(D-LD)and diamine oxidase(DAO),adverse drug reactions,and recurrence rate during follow-up were detected and compared before treatment and four weeks after treatment,respectively.Results:After two months of treatment,there was no significant difference in clinical efficacy between groups A and B(P>0.05).The total effective rate of Group C was higher than that of either Groups A or B(P<0.05).The recov-ery time after diarrhea,relief time of abdominal pain,and disappearance time of rectal bleeding in Group C were shorter than those in Groups A and B(P<0.05),but there was no difference between Groups A and B(P<0.05).After four weeks of treatment,the levels of TNF-αand CRP in all three groups decreased compared with those before treatment(P<0.05).There was no significant difference in TNF-αand CRP levels between Group B and Group A(P>0.05),but they decreased in Group C and became lower than those in Groups A and B(P<0.05).After four weeks of treatment,CD3+and CD4+levels were increased in all three groups.There were no significant differences in CD3+and CD4+levels between groups A and B(P>0.05),but the levels of CD3+and CD4+in Group C were higher than those in groups A and B(P<0.05).After 4 weeks of treatment,the levels of D-LD and DAO in all three groups decreased as compared with those before treatment(P<0.05).There was no significant difference in the levels of D-LD and DAO in Group B and Group A(P>0.05),while the levels of D-LD and DAO in Group C were lower than those in groups A and B(P<0.05).There was no significant difference in the total incidence of adverse drug reactions among the three groups(P>0.05).After followed up for 12 months,a recurrence rate of 25.00%(8/32)in Group A and 29.03%(9/31)in Group B were found.There was no difference in the recurrence rate between groups A and B(P>0.05).There was no recur-rence in Group C,and the recurrence rate was lower than that in Groups A and B(P<0.05).Conclusion:Patients with ulcera-tive colitis can benefit from the treatment with Lactobacillus casei and Kangfuxin liquid.However,compared with single treat-ment,combined treatment can improve the therapeutic effect,have a better impact on inflammation,immune function and intesti-nal mucosal function,and does not increase the risk of medication safety,with a low recurrence rate.
作者
汪静
杨以良
石保平
WANG Jing;YANG Yiliang;SHI Baoping(Department of Gastroenterology, Xinyang Central Hospital)
出处
《长治医学院学报》
2025年第4期322-326,335,共6页
Journal of Changzhi Medical College
关键词
溃疡性结肠炎
康复新液
干酪乳杆菌
肠道黏膜功能
ulcerative colitis
kangfuxin liquid
lactobacillus casei
intestinal mucosal function
